TP53 and leukemia: Senescence induction of p53‐competent nonstem leukaemia cells by adriamycin treatment leads to increased expression of leukaemia stem cell surface markers and upregulation of stem cell‐related transcripts, which was minimal in their p53‐deficient nonsenescent counterparts [186].